echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qilu's first over 100 million antihypertensive drug appraised the first domestically produced $1 billion variety

    Qilu's first over 100 million antihypertensive drug appraised the first domestically produced $1 billion variety

    • Last Update: 2022-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Recently, Qilu Pharmaceutical has made new progress in the field of hypertension medication: carvedilol tablets have been successfully reviewed, the first in China, and the sales of this product in China's public medical institutions will exceed 100 million yuan in 2020; Riociguat tablets reported It is the first domestically produced drug, and currently no generic drugs have been approved in China
    Source: State Food and Drug Administration's official website On March 31, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's carvedilol tablets were successfully evaluated, the first in China
    Carvedilol is an α and β receptor blocker, which can dilate blood vessels while blocking the receptors.
    It is clinically used for patients with mild to moderate hypertension or with renal insufficiency and diabetes.
    It can also be used to treat symptomatic patients.
    of congestive heart failure
    There are more than ten domestic companies that have the approval for the production of carvedilol tablets.
    According to Minet.
    com, the product will be used in urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals in China in 2020.
    Sales of more than 100 million yuan, of which Qilu Pharmaceutical exclusively occupies 70% of the market
    At present, only Qilu Pharmaceutical has submitted a supplementary application for the consistency evaluation of carvedilol tablets, and now it has successfully passed the evaluation, which is conducive to consolidating the original market
    The source of the hypertension drug Qilu Pharmaceutical recently reported: CDE official website On March 25, the CDE official website showed that Qilu Pharmaceutical was accepted by the CDE for its marketing application for generic 4 types of riociguat tablets
    Riociguat is a soluble guanylate cyclase (sGC) agonist, mainly used for the treatment of chronic thromboembolic pulmonary hypertension and arterial pulmonary hypertension, with global sales exceeding $1 billion in 2021
    Bayer's riociguat tablets were approved for import in September 2017 and have been negotiated into the national medical insurance category B catalog.
    According to data from Minet, the sales growth rate of this product in China's public medical institutions exceeded 200% in the first half of 2021.

    At present, only Qilu Pharmaceutical has submitted the listing application for Riociguat tablets under the new registration classification, and no company has started the BE trial of this product, so Qilu Pharmaceutical has a high probability of winning the first copy.

    Sources of drugs for hypertension that have been reviewed by Qilu Pharmaceuticals: Minenet MED2.
    0 China Drug Evaluation Database Home review, esmolol hydrochloride injection is the second review
    Source: Minet database, the official website of the State Food and Drug Administration, etc.
    Note: The statistics are as of April 1.
    If there are any omissions, please correct me!
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.